The treatment efficacy of immune checkpoint blockade in tumor patients varies by sex and age.292 Two systematic reviews and meta-analyses found that anti-PD-1/PD-L1 monotherapy was more effective in men, whereas the combination of anti-PD-1/PD-L1 chemotherapy was more beneficial to women with advanced lung cancer.293. Here, CD274 is linked to lung carcinoma.